axo-aav-gm2
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04669535)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ceramide glucosyltransferaseSupplementation
UGCG supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04669535 | Phase 1 | Dec 31, 2020 | Axovant Sciences Inc, Harvard University, University of Massachusetts |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Axovant Sciences Inc | For profit | 1 | 1 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1